One Mind's New Cohort Wields AI to Forge Mental Health's Future

MENLO PARK, CA – February 09, 2026 – A new wave of innovation is set to crash upon the shores of the global mental health crisis, propelled by a unique blend of high technology and mission-driven philanthropy. The One Mind Accelerator, a leading nonprofit program, today unveiled its fourth cohort, a select group of 14 startups chosen from a record-breaking pool of applicants, representing a less than 5% acceptance rate. These companies are poised to redefine mental healthcare, wielding advancements in clinical AI, non-invasive brain imaging, and precision drug discovery to address conditions spanning from pediatric anxiety to schizophrenia.

This announcement isn't just about promise; it's built on a foundation of proven success. The accelerator, launched in 2023, has cultivated a portfolio that is already demonstrating significant real-world results.

A Proven Model for Billion-Dollar Impact

Before welcoming its new class, the One Mind Accelerator has already established a formidable track record. The first 37 companies to pass through its intensive 10-week program have collectively raised nearly $1 billion in follow-on funding since their respective Demo Days. More importantly, their innovations have already reached and positively impacted over one million individuals living with mental health challenges.

This potent combination of financial success and tangible human benefit is the core of the accelerator's mission. "Since its launch, the One Mind Accelerator has focused on addressing the mental health crisis by helping early-stage companies bring their innovations to market faster and with greater impact," said Carmine Di Maro, Executive Director of the One Mind Accelerator, in a statement. The program’s success stems from providing hands-on support and facilitating critical connections within its vast network of experts, investors, and healthcare providers. Over 1,000 introductions and 300 expert sessions have been facilitated in just three years, leading directly to commercial contracts and the recruitment of top-tier talent for its portfolio companies.

The 2026 program continues this model, kicking off with an intensive in-person week featuring panels with senior government officials from agencies like the National Institute of Mental Health (NIMH) and the Advanced Research Projects Agency for Health (ARPA-H), alongside executives from major payers like Cigna and Optum and providers like Kaiser Permanente.

The AI Revolution in Psychiatry

This year's cohort stands out for its deep integration of cutting-edge technology, particularly artificial intelligence and advanced neuroscience, to create a future of "precision psychiatry." These startups are moving beyond one-size-fits-all solutions and toward personalized, data-driven care.

"This year's cohort represents the forefront of mental health science, innovation, and treatment," said Kathleen M. Pike, PHD, CEO of One Mind. "As technology, including AI, redefines what's possible, these founders are ready to meet the moment."

Several companies exemplify this technological inflection:
* Limbic: Already deployed in the UK and US, Limbic has developed a clinically-validated AI mental health chatbot that has supported over 600,000 patients. It stands as the only product of its kind to be approved as a Class II medical device, signaling a new era of regulated, scalable AI support tools.
* Flow Neuroscience: This company is pioneering "at-home electric medicine" with the world's first FDA-approved transcranial direct current stimulation (tDCS) headset for treating depression, offering a drug-free, brain-based treatment that patients can use themselves.
* Orbit Neuro: Aiming to create foundational models of cognitive states, Orbit Neuro is developing a novel brain wearable capable of achieving fMRI-comparable resolution at scale. This could unlock unprecedentedly rich neural datasets, revolutionizing diagnostics.
* Eratos Therapeutics and Forecast Bio: Both companies are leveraging AI to radically accelerate drug discovery for CNS disorders. Eratos creates AI-driven nanoscale maps of the brain to identify therapeutic targets, while Forecast maps how new drugs impact human brain circuits, aiming to speed up development by a factor of ten.

A Full-Spectrum Approach to Well-Being

While high-tech solutions for diagnosis and treatment are a major theme, the 2026 cohort also reflects a holistic understanding of mental health, addressing needs across the entire lifespan and spectrum of severity. The accelerator has selected companies tackling everything from behavioral addictions and loneliness to the specific needs of children and older adults.

Manatee, for instance, is a family mental health provider that treats the entire family system—not just the child—to address the pediatric mental health crisis. Its model is proven to be significantly more engaging and effective than traditional child-only therapy. On the other end of the age spectrum, Vitalic Health is a specialized behavioral health practice focused on proactive outreach to the often-reluctant geriatric population, a group with unique barriers to care.

Other startups are targeting emerging and often overlooked areas. Birches Health provides specialized, insurance-covered care for behavioral addictions like gambling, gaming, and social media. SocialRx is building a healthcare-grade platform to combat the loneliness epidemic by enabling "social prescribing" of arts, culture, and nature activities. This diverse portfolio underscores a commitment to leaving no one behind, ensuring that innovation addresses the multifaceted nature of the mental health crisis.

The Philanthropic Powerhouse Driving Change

Perhaps the most unique aspect of the One Mind Accelerator is its structure. As a 501(c)(3) nonprofit, it operates on a philanthropic model, a stark contrast to the equity-driven world of traditional venture capital. One Mind receives advisory shares from participating companies, but all proceeds from these shares are reinvested back into the nonprofit's mission.

This model, fueled by generous support from donors like the Baszucki Group, Penner Family Foundation, and Resonance Philanthropies, allows the accelerator to take risks on ventures that traditional VCs might deem too complex, too long-term, or not commercially viable enough. It enables a focus on areas of profound need, such as serious mental illness, which is being addressed by cohort companies like Biomia and Monument Therapeutics through novel drug development pipelines.

"One Mind Accelerator has been a great partner and feeder of innovative teams with the potential to dramatically change how patients are supported or treated, especially in youth mental health," noted Sheri Sobrato, Founder of Resonance Philanthropies and a long-time supporter.

This philanthropic backing creates an environment where the primary return on investment is human impact. It fosters a collaborative ecosystem where founders, mentors, and funders are all aligned on a single goal: transforming knowledge into actionable solutions that bring healing to the millions of individuals and families whose lives are impacted by mental illness. As this new cohort begins its 10-week journey, it carries not just the promise of technology, but the weight of a community dedicated to forging a healthier future.